Amarin Permax settlement

Ivax granted nonexclusive, U.S. sublicense under two patents to market generic version of Permax (pergolide mesylate) beginning Sept. 2 under a patent litigation settlement announced May 13. In exchange, Amarin will receive royalty payments to be shared with Lilly, which licenses the patents to Amarin, from the first six months' gross profit from sales of Ivax' product. Amarin began promoting the Parkinson's drug in 2001 under a deal with Elan, which originally sued Ivax for infringement. The 30-month stay expires in September. Ivax' ANDA received tentative approval in April. Teva, which was not sued for infringement, began marketing generic pergolide mesylate following its ANDA approval in November...